RNA

Avidity Biosciences (RNA) is the lead sponsor of 6 active clinical trials listed on ClinicalTrials.gov^[4], including 3 Phase 3^[1], 3 Phase 2^[2], 1 Phase 1^[3].

Trial NCT06411288^[5] evaluates AOC 1001 (del-desiran) in DM1 with a target enrollment of 159 participants. Trial NCT07008469^[6] evaluates Del-desiran (AOC 1001) in Myotonic Dystrophy Type 1 with a target enrollment of 230 participants. Trial NCT07038200^[7] evaluates AOC-1020 in Facioscapulohumeral Muscular Dystrophy with a target enrollment of 200 participants.

No Form 4 insider filings for RNA were recorded at the SEC in the past 30 days^[8].